Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis

Current Medical Research and Opinion

Volumn 33, Issue 3, 2017, Pages 553-562

  Qiu, Rong ^a   Balis, Dainius ^a   Xie, John ^a   Davies, Michael J ^a   Desai, Mehul ^a   Meininger, Gary ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Canagliflozin; safety; sodium glucose co transporter 2; type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ACUTE PANCREATITIS; ACUTE PYELONEPHRITIS; ADD ON THERAPY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BALANITIS; BALANOPOSTHITIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CHRONIC PANCREATITIS; CHRONIC PYELONEPHRITIS; CONTROLLED STUDY; CYSTITIS; DEHYDRATION; DIABETIC KETOACIDOSIS; DRUG SAFETY; DRUG TOLERABILITY; DRY THROAT; ENTEROCOCCAL INFECTION; ESTIMATED GLOMERULAR FILTRATION RATE; FAINTNESS; FEMALE; FEMALE GENITAL TRACT INFECTION; FRACTURE; GENITAL CANDIDIASIS; GENITAL TRACT INFECTION; HUMAN; HYPOGLYCEMIA; INCIDENCE; KIDNEY FAILURE; KIDNEY INFECTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT INFECTION; MICTURITION DISORDER; MONOTHERAPY; MYCOSIS; NEPHROLITHIASIS; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; ORTHOSTATIC INTOLERANCE; OSMOTIC DIURESIS; PANCREATITIS; POLLAKISURIA; POLYDIPSIA; POLYURIA; POST HOC ANALYSIS; PRESYNCOPE; PYELONEPHRITIS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TONGUE SWELLING; TREATMENT DURATION; UREMIA; URETER STONE; URINARY TRACT INFECTION; URINARY URGENCY; UROSEPSIS; VAGINA CANDIDIASIS; VAGINAL INFLAMMATION; VAGINITIS; VULVITIS; VULVOVAGINITIS; XEROSTOMIA; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYCOSES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85008227518     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1271780     Document Type: Article

References (37)

1. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
2. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy:a randomised trial. Diabetologia 2013;56:2582-92
3. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea:a randomised trial. Int J Clin Pract 2013;67:1267-82
4. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014;16:467-77
5. Stenlöf K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise:findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014;30:163-75
6. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU):52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
7. Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus:a randomized trial. Hosp Pract 2013;41:72-84
8. Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin:a randomized, double-blind, phase 3 study. Diabetes Care 2015;38:355-64
9. Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab 2015;17:294-303
10. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea:a 52-week, randomized trial. Diabetes Care 2013;36:2508-15
11. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
12. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 2014;16:1016-27
13. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015;38:403-11
14. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-45
15. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8
16. Sha S, Devineni D, Ghosh A, et al. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One 2014;9:e105638
17. Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013;53:601-10
18. Usiskin K, Kline I, Fung A, et al. Safety and tolerability of canagliflozin in patients with type 2 diabetes:pooled analysis of phase 3 study results. Postgrad Med 2014;126:16-34
19. US Food and Drug Administration. FDA drug safety communication:FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. Available at:http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm [Last accessed 22 July 2016]
20. US Food and Drug Administration. FDA drug safety communication:FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Available at:http://www.fda.gov/drugs/drugsafety/ucm475463.htm [Last accessed 22 July 2016]
21. Erondu N, Desai M, Ways K, Meininger G., Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015;38:1680-6
22. US Food and Drug Administration. FDA drug safety communication:FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. Available at:http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm [Last accessed 22 July 2016]
23. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016;101:157-66
24. US Food and Drug Administration. FDA briefing document:Endocrine and Metabolic Drug Advisory Committee Meeting, June 28, 2016. Available at:http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM508422.pdf [Last accessed 22 July 2016]
25. ® (canagliflozin) tablets, for oral use [package insert]. Titusville, NJ:Janssen Pharmaceuticals; 2016.
26. ® (dapagliflozin) tablets, for oral use [package insert]. Princeton, NJ:Bristol-Myers Squibb Company; 2016.
27. ® (empagliflozin) tablets, for oral use [package insert]. Ridgefield, CT:Boehringer Ingelheim Pharmaceuticals, Inc.; 2016.
28. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the CANagliflozin cardioVascular Assessment Study (CANVAS)–a randomized placebo-controlled trial. Am Heart J 2013;166:217-23
29. Weir M, Januszewicz A, Gilbert R, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2014;16:875-82
30. Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus:a pooled analysis of clinical studies. Curr Med Res Opin 2014;30:1109-19
31. Wilding JPH, Blonde L, Leiter LA, et al. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus. J Diabetes Complications 2015;29:438-44
32. Nicolle LE, Capuano G, Fung A, Usiskin K., Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 2014;126:7-17
33. Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:479-84
34. Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:473-8
35. Rosenthal N, Meininger G, Ways K, et al. Canagliflozin:a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci 2015;1358:28-43
36. Wu JH, Foote C, Blomster J, et al. Effects of sodium–glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes:a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016;4:411-9
37. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28